Thomas J. SchuetzCo-Founder and CEO at Compass Therapeutics
Dr. Schuetz, M.D., Ph.D., is the Co-Founder and Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed where he co-founded Audentes, now a publicly traded company where he remains a Director. Also at Orbimed, he was responsible for the investments in Enobia, Arteaus, and Relypsa where he served as a Director at each of these companies. Enobia was acquired by Alexion in 2011, Arteaus was acquired by Eli Lilly in 2014, and Relypsa was acquired by Galenica in 2016. Dr. Schuetz has multiple years of clinical strategy, development and operations experience including roles as Chief Medical Officer of Therion Biologics Corporation, a cancer vaccine company, and the Vice President of Clinical Affairs at Transkaryotic Therapies, a company acquired by Shire. Dr. Schuetz completed his medical training at Massachusetts General Hospital, where he served as the Chief Medical Resident, and completed his medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in Genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.